Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vaccine containing L1 capsid proteins from four types of HPV (ALPHAPAPILLOMAVIRUS), types 6, 11, 16 and 18 that is used to prevent infections from HUMAN PAPILLOMAVIRUSES of these subtypes.
| Descriptor ID |
D000068857
|
| MeSH Number(s) |
D20.215.894.899.498.500
|
| Concept/Terms |
Human Papillomavirus Vaccine L1, Type 6,11,16,18- Human Papillomavirus Vaccine L1, Type 6,11,16,18
- HPV L1 Vaccine, Quadrivalent 6,11,16,18
|
Below are MeSH descriptors whose meaning is more general than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
Below are MeSH descriptors whose meaning is more specific than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
This graph shows the total number of publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in this website by year, and whether "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in Profiles.
-
Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine. Front Cell Infect Microbiol. 2019; 9:59.
-
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018 10 15; 67(9):1339-1346.
-
High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis. 2018 04; 45(4):266-271.
-
Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine. 2014 Dec 05; 32(51):6941-6947.
-
The role of media and the Internet on vaccine adverse event reporting: a case study of human papillomavirus vaccination. J Adolesc Health. 2014 Mar; 54(3):289-95.
-
Human papillomavirus vaccine coverage among females aged 11 to 17 in Texas counties: an application of multilevel, small area estimation. Womens Health Issues. 2013 Mar-Apr; 23(2):e131-41.
-
Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy. 2011 Mar; 31(3):280-97.